Associated Papers
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
41351070 (PubMed )
Supplement: 12885_2025_15187_MOESM1_ESM.zip › Supp_Table_1.xlsx › Sheet1
Enhanced computational strategies for categorizing HER2 kinase domain variants of uncertain significance through structural and functional analysis.
Loganathan T et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society, 2025
Landscape of drug-resistance mutations in kinase regulatory hotspots.
Kim P et al.
Briefings in Bioinformatics, 2021
Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature.
Petrelli F et al.
Breast Cancer Research and Treatment, 2017
An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.
Hanker AB et al.
Cancer Discovery, 2017
ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas.
Deniziaut G et al.
Oncotarget, 2016
Structure-functional prediction and analysis of cancer mutation effects in protein kinases.
Dixit A et al.
Computational and Mathematical Methods in Medicine, 2014
CanDrA: cancer-specific driver missense mutation annotation with optimized features.
Mao Y et al.
Plos One, 2013
24205039 (PubMed )
Supplement: pone.0077945.s001.xls › Table_S10
Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.
Lee JW et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2006
Select a paper to view details